Research programme: peptide based antibiotics - SinSa Labs

Drug Profile

Research programme: peptide based antibiotics - SinSa Labs

Alternative Names: AM 009; AM 016; AM 052; AM 218; Dorzidin B2088; Dorzidin™; SHT peptides; SpearHead Antibiotics

Latest Information Update: 16 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SinSa Labs
  • Class Peptides; Peptidomimetics; Small molecules
  • Mechanism of Action Membrane glycoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Mycobacterial infections; Mycoses

Most Recent Events

  • 13 Jan 2015 Adverse events and pharmacodynamics data from preclinical trials in Bacterial infections released by SinSa Labs
  • 08 Jan 2015 SinSa Labs in-licenses antibiotic technology platform from Exploit Technologies
  • 01 Dec 2014 Preclinical trials in Bacterial infections in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top